Literature DB >> 22820478

Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery.

Rodolphe Anty1, Sophie Marjoux, Antonio Iannelli, Stéphanie Patouraux, Anne-Sophie Schneck, Stéphanie Bonnafous, Camille Gire, Anca Amzolini, Imed Ben-Amor, Marie-Christine Saint-Paul, Eugenia Mariné-Barjoan, Alexandre Pariente, Jean Gugenheim, Philippe Gual, Albert Tran.   

Abstract

BACKGROUND & AIMS: The aim of this study was to determine the influence of coffee and other caffeinated drinks on liver fibrosis of severely obese European patients.
METHODS: A specific questionnaire exploring various types of coffee (regular filtrated coffee and espresso), caffeinated drinks, and chocolate was filled in by 195 severely obese patients. All patients had liver biopsies that were analyzed according to the NASH Clinical Research Network Scoring System. Univariate and multivariate analyses of significant fibrosis were performed.
RESULTS: Caffeine came mainly from coffee-containing beverages (77.5%). Regular coffee and espresso were consumed in 30.8% and 50.2% of the patients, respectively. Regular coffee, espresso, and total caffeine consumption was similar between patients with and without NASH. While consumption of espresso, caffeinated soft drinks, and chocolate was similar among patients, with respect to the level of fibrosis, regular coffee consumption was lower in patients with significant fibrosis (F ≥2). According to logistic regression analysis, consumption of regular coffee was an independent protective factor for fibrosis (OR: 0.752 [0.578-0.980], p=0.035) in a model including level of AST (OR: 1.04 [1.004-1.076], p=0.029), presence of NASH (OR: 2.41 [1.007-5.782], p=0.048), presence of the metabolic syndrome (NS), and level of HOMA-IR (NS). Espresso, but not regular coffee consumption was higher in patients with lower HDL cholesterol level, higher triglyceride level, and the metabolic syndrome.
CONCLUSIONS: Consumption of regular coffee but not espresso is an independent protective factor for liver fibrosis in severely obese European patients.
Copyright © 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22820478     DOI: 10.1016/j.jhep.2012.07.014

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  36 in total

1.  Lifestyle Interventions Beyond Diet and Exercise for Patients With Nonalcoholic Fatty Liver Disease.

Authors:  James Philip Esteban; Amreen Dinani
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-03

Review 2.  Management of NAFLD: a stage-based approach.

Authors:  Mary E Rinella; Arun J Sanyal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-02-24       Impact factor: 46.802

3.  Coffee: a panacea or snake oil for the liver?

Authors:  Radhika Kumari; W Ray Kim
Journal:  Clin Gastroenterol Hepatol       Date:  2014-04-24       Impact factor: 11.382

4.  Drinking coffee burns hepatic fat by inducing lipophagy coupled with mitochondrial β-oxidation.

Authors:  Wen-Xing Ding
Journal:  Hepatology       Date:  2014-02-14       Impact factor: 17.425

Review 5.  Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic.

Authors:  Kareem Hassan; Varun Bhalla; Mohammed Ezz El Regal; H Hesham A-Kader
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

6.  Coffee, caffeine and non-alcoholic fatty liver disease?

Authors:  Oliver John Kennedy; Paul Roderick; Robin Poole; Julie Parkes
Journal:  Therap Adv Gastroenterol       Date:  2016-03-11       Impact factor: 4.409

Review 7.  Practical Dietary Recommendations for the Prevention and Management of Nonalcoholic Fatty Liver Disease in Adults.

Authors:  Elena S George; Adrienne Forsyth; Catherine Itsiopoulos; Amanda J Nicoll; Marno Ryan; Siddharth Sood; Stuart K Roberts; Audrey C Tierney
Journal:  Adv Nutr       Date:  2018-01-01       Impact factor: 8.701

Review 8.  Coffee and Liver Disease.

Authors:  Manav Wadhawan; Anil C Anand
Journal:  J Clin Exp Hepatol       Date:  2016-02-27

Review 9.  Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials.

Authors:  Shira Zelber-Sagi; Justyna Godos; Federico Salomone
Journal:  Therap Adv Gastroenterol       Date:  2016-03-17       Impact factor: 4.409

Review 10.  Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis.

Authors:  M Noureddin; Q M Anstee; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2016-04-08       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.